Related Experiment Video
Updated: Feb 6, 2026

RNA Catalyst as a Reporter for Screening Drugs against RNA Editing in Trypanosomes
Published on: July 22, 2014
Fixed drug eruption related to sunitinib: a case report
Anuradha Bhatia, Niharika Jha1, Bimal Kanish
1Department of Dermatology, Dr. BC Roy Post Graduate Institute of Pediatric Sciences, Kolkata. niharikajha88@gmail.com.
Abstract:
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor. It has been approved for the treatment of gastro-intestinal stromal tumor and advanced renal cell carcinoma. Fixed drug eruption related to sunitinib is a rare cutaneous adverse drug reaction.
Insights
Sunitinib, a targeted cancer therapy, can rarely cause a specific skin reaction known as fixed drug eruption. This condition is an uncommon adverse effect of this important tyrosine kinase inhibitor medication.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Sunitinib is an oral multi-targeted tyrosine kinase inhibitor.
- It is approved for treating gastro-intestinal stromal tumor and advanced renal cell carcinoma.
- Cutaneous adverse drug reactions are potential side effects of cancer therapies.
Related Concept Videos
Fixed Action Patterns
Fixing Double-strand Breaks
Data Reporting and Recording
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
Growth versus Fixed Mindset
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...

